Q1 Earnings Forecast for ALGN Issued By Leerink Partnrs

Align Technology, Inc. (NASDAQ:ALGN) – Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Align Technology in a note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now expects that the medical equipment provider will post earnings of $1.51 per share for the quarter, down from their previous estimate of $1.56. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s FY2028 earnings at $11.35 EPS.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 EPS for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%.

Other research analysts have also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and issued a $235.00 price target (down previously from $270.00) on shares of Align Technology in a research note on Tuesday, March 18th. Evercore ISI upped their target price on shares of Align Technology from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Jefferies Financial Group dropped their price target on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company initiated coverage on shares of Align Technology in a report on Friday, February 14th. They set an “overweight” rating and a $255.00 price objective for the company. Finally, Morgan Stanley dropped their target price on shares of Align Technology from $280.00 to $272.00 and set an “overweight” rating on the stock in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Align Technology presently has a consensus rating of “Moderate Buy” and a consensus price target of $262.64.

Align Technology Trading Up 2.5 %

ALGN stock opened at $164.14 on Friday. The stock’s 50 day simple moving average is $177.26 and its 200 day simple moving average is $207.35. Align Technology has a 12-month low of $141.74 and a 12-month high of $327.49. The stock has a market capitalization of $12.02 billion, a PE ratio of 29.26, a price-to-earnings-growth ratio of 2.24 and a beta of 1.73.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in Align Technology by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,790,014 shares of the medical equipment provider’s stock valued at $372,299,000 after acquiring an additional 39,209 shares during the period. Ninety One UK Ltd increased its position in Align Technology by 3.7% in the fourth quarter. Ninety One UK Ltd now owns 1,220,601 shares of the medical equipment provider’s stock worth $254,508,000 after purchasing an additional 43,524 shares during the last quarter. Invesco Ltd. raised its stake in Align Technology by 17.1% during the fourth quarter. Invesco Ltd. now owns 1,082,162 shares of the medical equipment provider’s stock valued at $225,642,000 after purchasing an additional 158,312 shares in the last quarter. Norges Bank purchased a new position in shares of Align Technology in the 4th quarter worth $190,792,000. Finally, Meridiem Investment Management Ltd. increased its holdings in shares of Align Technology by 63.7% in the 4th quarter. Meridiem Investment Management Ltd. now owns 764,732 shares of the medical equipment provider’s stock worth $159,470,000 after buying an additional 297,472 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.